

Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction

Nona Sotoodehnia^{1,2,78*}, Aaron Isaacs^{3,4,78}, Paul I W de Bakker^{5-8,78}, Marcus Dörr^{9,78}, Christopher Newton-Cheh^{10-12,78}, Ilja M Nolte^{13,78}, Pim van der Harst^{14,78}, Martina Müller^{15-17,78}, Mark Eijgelsheim^{18,78}, Alvaro Alonso^{19,78}, Andrew A Hicks^{20,78}, Sandosh Padmanabhan^{21,78}, Caroline Hayward^{22,78}, Albert Vernon Smith^{23,24,78}, Ozren Polasek^{25,78}, Steven Giovannone^{26,78}, Jingyuan Fu^{13,27,78}, Jared W Magnani^{12,28}, Kristin D Marcianti², Arne Pfeufer^{20,29,30}, Sina A Gharib³¹, Alexander Teumer³², Man Li³³, Joshua C Bis², Fernando Rivadeneira^{18,34}, Thor Aspelund^{23,24}, Anna Köttgen³⁵, Toby Johnson^{36,37}, Kenneth Rice³⁸, Mark P S Sie³, Ying A Wang^{12,39}, Norman Klopp¹⁷, Christian Fuchsberger²⁰, Sarah H Wild⁴⁰, Irene Mateo Leach¹⁴, Karol Estrada³⁴, Uwe Völker³², Alan F Wright²², Folkert W Asselbergs^{13,14,41}, Jiaxiang Qu²⁶, Aravinda Chakravarti⁴², Moritz F Sinner¹⁶, Jan A Kors⁴³, Astrid Petersmann⁴⁴, Tamara B Harris⁴⁵, Elsayed Z Soliman⁴⁶, Patricia B Munroe^{36,37}, Bruce M Psaty^{2,47-49}, Ben A Oostra^{4,50}, L Adrienne Cupples^{12,39}, Siegfried Perz⁵¹, Rudolf A de Boer¹⁴, André G Uitterlinden^{18,34,52}, Henry Völzke⁵³, Timothy D Spector⁵⁴, Fang-Yu Liu²⁶, Eric Boerwinkle^{55,56}, Anna F Dominiczak²¹, Jerome I Rotter⁵⁷, Gé van Herpen⁴³, Daniel Levy^{12,58}, H-Erich Wichmann^{15,17,59}, Wiek H van Gilst¹⁴, Jacqueline C M Witteman^{18,52}, Heyo K Kroemer⁶⁰, W H Linda Kao³³, Susan R Heckbert^{2,47,49}, Thomas Meitinger^{29,30}, Albert Hofman^{18,52}, Harry Campbell⁴⁰, Aaron R Folsom¹⁹, Dirk J van Veldhuisen¹⁴, Christine Schwenbacher^{20,61}, Christopher J O'Donnell^{12,58}, Claudia Beu Volpato²⁰, Mark J Caulfield^{36,37}, John M Connell⁶², Lenore Launer⁴⁵, Xiaowen Lu¹³, Lude Franke^{27,63}, Rudolf S N Fehrmann²⁷, Gerard te Meerman²⁷, Harry J M Groen⁶⁴, Rinse K Weersma⁶⁵, Leonard H van den Berg⁶⁶, Cisca Wijmenga²⁷, Roel A Ophoff^{67,68}, Gerjan Navis⁶⁹, Igor Rudan^{40,70,71,78}, Harold Snieder^{13,54,78}, James F Wilson^{40,78}, Peter P Pramstaller^{20,72,73,78}, David S Siscovick^{2,47,78}, Thomas J Wang^{11,12,78}, Vilmundur Gudnason^{23,24,78}, Cornelia M van Duijn^{3,4,52,78}, Stephan B Felix^{9,78}, Glenn I Fishman^{26,78}, Yalda Jamshidi^{54,74,78}, Bruno H Ch Stricker^{18,34,43,52,75,78}, Nilesh J Samani⁷⁶⁻⁷⁸, Stefan Käb^{16,78} & Dan E Arking^{42,78}

The QRS interval, from the beginning of the Q wave to the end of the S wave on an electrocardiogram, reflects ventricular depolarization and conduction time and is a risk factor for mortality, sudden death and heart failure. We performed a genome-wide association meta-analysis in 40,407 individuals of European descent from 14 studies, with further genotyping in 7,170 additional Europeans, and we identified 22 loci associated with QRS duration ($P < 5 \times 10^{-8}$). These loci map in or near genes in pathways with established roles in ventricular conduction such as sodium channels, transcription factors and calcium-handling proteins, but also point to previously unidentified biologic processes, such as kinase inhibitors and genes related to tumorigenesis. We demonstrate that *SCN10A*, a candidate gene at the most significantly associated locus in this study, is expressed in the mouse ventricular conduction system, and treatment with a selective *SCN10A* blocker prolongs QRS duration. These findings extend our current knowledge of ventricular depolarization and conduction.

The electrocardiographic QRS interval reflects ventricular depolarization, and its duration is a function of electrophysiological properties within the His-Purkinje system and the ventricular myocardium. A diseased ventricular conduction system can lead to life-threatening bradyarrhythmias, such as heart block, and tachyarrhythmias, such as ventricular fibrillation. Longer QRS duration is a predictor of mortality


and sudden death in the general population and in cohorts with hypertension and coronary artery disease¹⁻³. In a population-based study, prolonged baseline QRS was associated with incident heart failure⁴.

Twin and family studies suggest a genetic contribution to QRS duration, with heritability estimates of up to 40% (refs 5,6). Prior candidate gene and smaller genome-wide studies identified a limited

*A full list of author affiliations appears at the end of the paper.

Received 3 May; accepted 19 October; published online 14 November 2010; doi:10.1038/ng.716

Figure 1 Manhattan plot. Manhattan plot showing the association of SNPs with QRS interval duration in a GWAS of 40,407 individuals. The dashed horizontal line marks the threshold for genome-wide significance ($P = 5 \times 10^{-8}$). Twenty loci (labeled) reached genome-wide significance. Two additional loci, *GOSR2* and *DKK1*, reached significance after genotyping of select SNPs in an additional sample of 7,170 individuals (see results section of the main text).



number of loci associated with QRS duration, supporting the hypothesis of the contribution of common genetic variation in QRS duration^{7–9}. To identify additional loci and highlight physiologic processes associated with ventricular conduction, we performed a meta-analysis of 14 genome-wide association studies (GWAS) of QRS duration in a total of 40,407 individuals of European descent, where we adjusted the analyses for age, sex, height and body mass index (BMI) after appropriate sample exclusions (Online Methods). After an initial discovery phase, we further genotyped selected variants representing nine loci with P values ranging from $P = 1 \times 10^{-6}$ to $P = 5 \times 10^{-9}$ in an additional cohort of 7,170 European individuals.

RESULTS

Meta-analysis of genome-wide association results

We conducted meta-analyses for approximately 2.5 million SNPs in 40,407 individuals of European ancestry from 14 GWAS (Supplementary Table 1a,b). Overall, 612 variants in 20 loci exceeded our genome-wide significance P value threshold of $P = 5 \times 10^{-8}$ after adjusting for modest genomic inflation (genomic inflation factor (λ_{GC}) = 1.059) (Fig. 1 and Supplementary Fig. 1). The loci associated with QRS interval duration are detailed in Table 1 and Supplementary Figure 2, with the index SNP (representing the most significant association) labeled for each independent signal.

Across the genome, the most significant association for QRS interval duration (termed locus 1) was on chromosome 3p22 (Fig. 2a), where we identified six potentially independent association signals based on the linkage disequilibrium (LD) patterns in the HapMap European CEU population (pairwise r^2 among all index SNPs was < 0.05). In conditional analyses where all six SNPs were included in the same regression model, there was compelling evidence that at least four SNPs from this region were independently associated with QRS duration (Table 1). Two of these associations were in or near *SCN10A*, which encodes a voltage-gated sodium channel. Variation at this locus was recently associated with QRS duration in two GWAS. The top SNP identified in those two studies, rs6795970, is in strong LD with our top signal, rs6801975 ($r^2 = 0.93$)^{8,9}. Two additional signals were identified in *SCN5A*, a sodium channel gene adjacent to *SCN10A* (Table 1).

The second most significant locus (locus 2) was on chromosome 6p21 near *CDKN1A*, which encodes a cyclin-dependent kinase inhibitor. The *CDKN1A* locus was recently associated with QRS interval duration in an Icelandic population⁹. The index SNP in the prior report, rs1321311, is in strong LD with our top signal, rs9470361 ($r^2 = 0.88$). *CDKN2C*, which encodes another cyclin-dependent kinase inhibitor, is located in locus 15, which encompasses several other genes, including *C1orf185*, *RNF11* and *FAF1*.

Locus 3 on chromosome 6q22 contains the *PLN-SLC35F1-C6orf204-BRD7P3* cluster of genes. *PLN* encodes phospholamban, a key regulator of sarcoplasmic reticulum calcium reuptake. Significant associations were found in several other regions harboring calcium-handling genes, including locus 12 (*STRN-HEATR5B*), locus 16 (*PRKCA*) and locus 18 (*CASQ2*).

Locus 4 mapped to an intronic SNP in *NFIA*, which encodes a transcription factor. Several other significant loci also mapped in or near

genes encoding transcription factors, including locus 5 (*HAND1*), locus 6 (*TBX20*), locus 8 (*TBX5*), locus 9 (*TBX3*) and locus 19 (*KLF12*). Common variation in *TBX5* was recently associated with QRS duration⁹. The index signal in the prior report, rs3825214, was in moderate LD with our top signal, rs883079 ($r^2 = 0.67$).

Additional regions identified include locus 7 (*SIPA1L1*), locus 10 (*VTI1A*), locus 11 (*SETBP1*), locus 13 (*TKT-CACNA1D-PRKCD*), locus 14 (*CRIM1*), locus 17 (the nearest gene, *IGFBP3*, is 660 kb away) and locus 20 (*LRIG1*).

Collectively, the identified index SNPs across these 20 loci explained approximately 5.7% ($\pm 2.3\%$ (s.d.)) of the observed variance in QRS duration, consistent with a polygenic model in which each of the discovered variants exerts only a modest effect on QRS interval. None of these index SNPs showed a significant interaction with sex or age after Bonferroni correction (Supplementary Table 2). We observed moderate levels of heterogeneity of the effect ($25 < I^2 < 75$) for several index SNPs (Table 1). However, only *HAND1-SAP30L* showed significant evidence of heterogeneity using Cochran's Q test corrected for 23 independent genome-wide variants (Cochran's $P = 0.005$).

Extension of findings in an additional 7,170 individuals

Based on the discovery meta-analysis, we selected the index SNPs at four loci (loci 15, 17, 19 and 20) with P values ranging between $P = 5 \times 10^{-8}$ and $P = 5 \times 10^{-9}$ and from all five loci with P values ranging from $P = 1 \times 10^{-6}$ to $P = 5 \times 10^{-8}$ (Online Methods) for genotyping in an additional 7,170 European individuals in order to boost the study's power. In a joint analysis combining all 47,577 individuals, the significance for the four loci with P values between $P = 5 \times 10^{-8}$ and $P = 5 \times 10^{-9}$ increased, indicating these represent true positive associations (Table 1). The joint analysis also provided further evidence for two other loci (locus 21 near *DKK1* and locus 22 tagged by an intronic SNP in *GOSR2*) that reached genome-wide significance, bringing the total number of significant loci to 22, with 25 independently associated index SNPs (Table 1). The index SNP (rs1733724) in *DKK1* was previously associated with QRS duration in an Icelandic population⁹.

Association with conduction defect

Based on this series of QRS associations, we sought to test the hypothesis that QRS-prolonging alleles, on average, increase risk of ventricular conduction defects. To address this question, we calculated a risk score in each individual by adding up the number of QRS-prolonging alleles identified in this study weighted by the observed effect sizes (β estimates) from the final meta-analysis. In an independent set of 519 individuals from the Atherosclerosis Risk in Communities (ARIC) and Rotterdam (RS) studies with bundle branch block or nonspecific prolongation of QRS interval (QRS > 120 milliseconds (ms)) compared with those individuals with normal conduction ($N = 12,804$), we found evidence that the cumulative burden of QRS-prolonging alleles is associated with risk of ventricular conduction defect ($P = 0.004$). This result was largely driven by those individuals with nonspecific

Table 1 Significant loci at $P < 5 \times 10^{-8}$ in combined GWAS and candidate SNP meta-analysis

Locus	Chr.	Index SNP	Coded/ non-coded Allele	AF	GWAS β	GWAS s.e. _{GC}	GWAS P_{GC}	r^2	PREVEND		$P_{Overall}$	Multi- SNP β	Multi- SNP P	Nearest gene	SNP annotation
									β	P					
1	3	rs6801957	T/C	0.41	0.77	0.07	1.10×10^{-28}	45.3	—	—	1.10×10^{-28}	0.54	3.43×10^{-14}	<i>SCN10A</i>	Intron
		rs9851724	C/T	0.33	-0.66	0.07	1.91×10^{-20}	57.1	—	—	1.91×10^{-20}	-0.60	5.78×10^{-16}	<i>SCN10A-SCN5A</i>	Intergenic
		rs10865879	T/C	0.41	0.77	0.07	1.10×10^{-28}	53.6	—	—	1.10×10^{-28}	0.33	1.67×10^{-4}	<i>SCN5A/EXOG</i>	Intergenic
		rs11710077	T/A	0.21	-0.84	0.09	5.74×10^{-22}	23.8	—	—	5.74×10^{-22}	-0.44	1.33×10^{-6}	<i>SCN5A</i>	Intron
		rs11708996	C/G	0.16	0.79	0.10	1.26×10^{-16}	0.0	—	—	1.26×10^{-16}	0.47	7.23×10^{-6}	<i>SCN5A</i>	Intron
3	rs2051211	G/A	0.26	-0.44	0.08	1.57×10^{-8}	0.0	—	—	1.57×10^{-8}	-0.18	3.71×10^{-2}	<i>EXOG</i>	Intron	
2	6	rs9470361	A/G	0.25	0.87	0.08	3.00×10^{-27}	14.6	—	—	3.00×10^{-27}	—	—	<i>CDKN1A</i>	Intergenic
3	6	rs11153730	C/T	0.49	0.59	0.07	1.26×10^{-18}	5.3	—	—	1.26×10^{-18}	—	—	<i>C6orf204- SLC35F1- PLN-BRD7P3</i>	Intergenic
4	1	rs9436640	G/T	0.46	-0.59	0.07	4.57×10^{-18}	51.2	—	—	4.57×10^{-18}	—	—	<i>NFIA</i>	Intron
5	5	rs13165478	A/G	0.36	-0.55	0.07	7.36×10^{-14}	64.6	—	—	7.36×10^{-14}	—	—	<i>HAND1-SAP30L</i>	Intergenic
6	7	rs1362212	A/G	0.18	0.69	0.09	1.12×10^{-13}	0.0	—	—	1.12×10^{-13}	—	—	<i>TBX20</i>	Intergenic
7	14	rs11848785	G/A	0.27	-0.50	0.08	1.04×10^{-10}	0.0	—	—	1.04×10^{-10}	—	—	<i>SIPA1L1</i>	Intron
8	12	rs883079	C/T	0.29	0.49	0.08	1.33×10^{-10}	8.3	—	—	1.33×10^{-10}	—	—	<i>TBX5</i>	3' UTR
9	12	rs10850409	A/G	0.27	-0.49	0.08	3.06×10^{-10}	0.0	—	—	3.06×10^{-10}	—	—	<i>TBX3</i>	Intergenic
10	10	rs7342028	T/G	0.27	0.48	0.08	4.95×10^{-10}	0.0	—	—	4.95×10^{-10}	—	—	<i>VT11A</i>	Intron
11	18	rs991014	T/C	0.42	0.42	0.07	6.20×10^{-10}	0.0	—	—	6.20×10^{-10}	—	—	<i>SETBP1</i>	Intron
12	2	rs17020136	C/T	0.21	0.51	0.08	1.90×10^{-9}	0.0	—	—	1.90×10^{-9}	—	—	<i>HEATR5B-STRN</i>	Intron
13	3	rs4687718	A/G	0.14	-0.63	0.11	6.25×10^{-9}	0.0	—	—	6.25×10^{-9}	—	—	<i>TKT-PRKCD- CACNA1D</i>	Intron
14	2	rs7562790	G/T	0.40	0.39	0.07	8.22×10^{-9}	0.0	—	—	8.22×10^{-9}	—	—	<i>CRIM1</i>	Intron
15	1	rs17391905	G/T	0.05	-1.35	0.23	8.72×10^{-9}	4.0	-1.17	0.005	3.26×10^{-10}	—	—	<i>C1orf185- RNF11- CDKN2C-FAF1</i>	Intergenic
16	17	rs9912468	G/C	0.43	0.39	0.07	1.06×10^{-8}	28.2	—	—	1.06×10^{-8}	—	—	<i>PRKCA</i>	Intron
17	7	rs7784776	G/A	0.43	0.39	0.07	1.42×10^{-8}	0.0	0.36	0.015	1.28×10^{-9}	—	—	<i>IGFBP3</i>	Intergenic
18	1	rs4074536	C/T	0.29	-0.42	0.07	2.36×10^{-8}	0.5	—	—	2.36×10^{-8}	—	—	<i>CASQ2</i>	Missense
19	13	rs1886512	A/T	0.37	-0.40	0.07	4.31×10^{-8}	0.0	-0.28	0.047	1.27×10^{-8}	—	—	<i>KLF12</i>	Intron
20	3	rs2242285	A/G	0.42	0.37	0.07	4.79×10^{-8}	35.4	0.29	0.040	1.09×10^{-8}	—	—	<i>LRIG1- SLC25A26</i>	Intron
21	10	rs1733724	A/G	0.25	0.49	0.09	1.26×10^{-7}	0.0	0.34	0.035	3.05×10^{-8}	—	—	<i>DKK1</i>	Intergenic
22	17	rs17608766	C/T	0.16	0.53	0.10	3.71×10^{-7}	13.8	0.92	4.7×10^{-5}	4.75×10^{-10}	—	—	<i>GOSR2</i>	Intron, 3' UTR

In each locus, at least one marker exceeded the genome-wide significance threshold of $P < 5 \times 10^{-8}$. At locus 1, six signals were identified ($r^2 < 0.05$) that exceeded this genome-wide threshold. In a multi-SNP model that included all six SNPs, there was evidence that at least four of these SNPs were independently associated with QRS duration. The bolded allele is the coded allele. β values estimate the difference in QRS interval in milliseconds per copy of the coded allele, adjusted for the covariates in the model. Chr., chromosome; AF, coded allele frequency; s.e., standard error; GC, genomic-control adjusted; UTR, untranslated region. AF is an average weighted by study size.

intraventricular conduction defects, as opposed to those with left or right bundle branch block (**Supplementary Table 3a,b**). Similar results were observed using an unweighted genotype risk score.

Putative functional variants

Of the 612 genome-wide significant SNPs, one in *SCN5A* (rs1805124, His558Arg, $P = 2.4 \times 10^{-18}$), two in *SCN10A* (rs12632942, Leu1092Pro, $P = 5.1 \times 10^{-11}$, and rs6795970, Ala1073Val, $P = 5 \times 10^{-27}$), one in *C6orf204* near *PLN* (rs3734381, Ser137Gly, $P = 1.1 \times 10^{-10}$) and one in *CASQ2* (index SNP rs4074536, Thr66Ala, $P = 2.4 \times 10^{-8}$) were non-synonymous (**Fig. 2** and **Supplementary Fig. 2**). The PolyPhen-2 program predicts all five of these variants to be benign, which is consistent with small-effect associations: each copy of the minor allele was associated with cross-sectional differences in QRS duration of less than 1 ms.

The 25 index SNPs (**Table 1**) were subsequently tested for association with gene *cis* expression levels in 1,240 PAXgene whole blood samples¹⁰. Four *cis* expression QTLs (eQTLs) were detected after stringent Bonferroni correction (**Supplementary Fig. 3**). The most notable eQTLs were observed for probes in exonic regions of *TKT* (rs4687718, $P = 5.87 \times 10^{-70}$) and *CDKN1A* (rs9470361, $P = 1.41 \times 10^{-10}$) and in an intronic probe for *C6orf204* near *PLN* (rs11153730,

$P = 1.54 \times 10^{-10}$). We additionally assessed *cis* regulation for all HapMap SNPs for these three loci (± 250 kb around the SNPs). The top eSNPs for *TKT* (rs9821134) and *C6orf204* (rs11970286) were in moderate to high LD ($r^2 = 0.47$ and $r^2 = 0.91$, respectively) with the top QRS signals at these loci. However, the top eSNP for *CDKN1A*, rs735013, was only weakly correlated with the QRS index SNP rs9470361 ($r^2 = 0.089$). In a conditional analysis that included both *CDKN1A* locus SNPs in the regression model, both rs735013 and rs9470361 remained independently associated with expression levels ($P = 1.7 \times 10^{-9}$ and $P = 2.3 \times 10^{-5}$, respectively). Additionally, rs735013 itself was marginally associated with QRS duration (coded allele frequency = 0.39, $\beta = 0.33$ ms (s.e. = 0.07 ms), $P = 2.4 \times 10^{-6}$). Whether these associations in whole blood samples will be similar to associations in cardiac myocytes and conduction tissue deserves further investigation.

Pleiotropic effects of ECG-associated variants

To explore the shared genetic underpinnings between atrial and ventricular depolarization and conduction (as measured by PR and QRS intervals) as well as ventricular depolarization and repolarization (QRS and QT intervals), we examined the effects of previously published PR and QT SNPs with respect to QRS interval. Several QRS loci were


Figure 2 Association plots for select loci. Each SNP is plotted with respect to its chromosomal location (*x* axis) and its *P* value (y axis on the left). The tall blue spikes indicate the recombination rate (y axis on the right) at that region of the chromosome. The blue-outlined triangles indicate coding region SNPs. (a) Locus 1 (*SCN5A-SCN10A*) on chromosome 3. The six index signals are named with their rs numbers and highlighted in different colors (yellow, green, teal, blue, purple and red). Other SNPs in linkage disequilibrium with the index SNP are denoted in the same color. Color saturation indicates the degree of correlation with the index SNP. (b) Locus 8 (*TBX5*) and locus 9 (*TBX3*) on chromosome 12. (c) Locus 12 (*HEATR5B-STRN*) and locus 14 (*CRIM1*) on chromosome 2.

previously associated with PR or QT intervals, including *PLN*, *TBX5-TBX3* and *SCN5A-SCN10A*, the last of which is associated with all three traits (**Supplementary Table 4a**). We also tested 9 PR SNPs and 16 QT SNPs for their effect on QRS duration (**Supplementary Table 4b**)^{11–13}. Our results suggest roles for *CAV1-CAV2* (rs3807989, $P = 5.8 \times 10^{-6}$) and *NOS1AP* (rs12143842, $P = 1.3 \times 10^{-4}$) in QRS duration. Indeed *CAV1-CAV2* was recently associated with QRS interval⁹.

QRS duration is positively correlated with both PR interval ($r = 0.09$) and QT interval ($r = 0.44$)⁹. To test if these relationships are also observed genetically, we compared the directionality of the association of SNPs at the published PR and QT loci with those for QRS duration. Generally, the effects of SNPs on PR interval were positively correlated with their effects on QRS duration ($r = 0.53$). With the exception of *TBX3*, the loci influencing both PR and QRS intervals (*SCN5A*, *SCN10A*, *TBX5* and *CAV1-CAV2*) do so in a concordant fashion (that is, variants that prolong PR also prolong QRS duration) (**Fig. 3** and **Supplementary Table 4a,b**). By contrast, although QT and QRS are positively correlated at the population level, the effects of SNPs on QT interval were marginally negatively correlated with their effects on QRS interval ($r = -0.08$). Of the index SNPs at the four loci significantly associated with both QT and QRS interval (*SCN5A-SCN10A*, *PRKCA*, *NOS1AP* and *PLN*), only the *PLN* locus SNPs showed effects in the same direction (**Fig. 3** and **Supplementary Table 4a,b**).

Bioinformatic network analysis of QRS-associated loci

To examine the relationships between genetic loci associated with QRS duration, we developed an *in silico* relational network linking the loci based on published direct gene product interactions obtained from curated databases (**Supplementary Fig. 4**)¹⁴. Most loci meeting genome-wide significance mapped to this network after a minimum number of ‘linker’ nodes were incorporated to create a spanning



network. This analysis provides a graphical overview of the interconnections among QRS-associated genetic loci and highlights both known and putative molecular mechanisms regulating ventricular conduction (see below for further discussion). Several of the ‘linker’ nodes incorporated in the network, such as *GJA1* (encoding connexin 43), *NEDD4*, *KCNMA1* and *RYR2*, are known modulators of cardiac electrical activity. Functional enrichment analysis of the QRS-associated network nodes (that is, loci with $P < 5 \times 10^{-8}$) using two independent software tools revealed that programs involved in heart development were highly overrepresented (P value range: $P = 5.8 \times 10^{-6}$ to $P = 9.6 \times 10^{-5}$)^{15,16}.

SCN10A function in a mouse model

We undertook functional studies to determine whether our most significant locus was associated with ventricular conduction in mice. Transcriptional profiling suggests that *Scn10a* mRNA, which encodes the $Na_v1.8$ sodium channel, is expressed in the ventricular myocardium and at higher levels in the specialized conduction system¹⁷. These data were confirmed and extended by quantitative





Figure 3 Pleiotropic associations of PR, QRS and QT loci. Electrocardiographic tracing delineating the PR, QRS and QT intervals. PR and QRS intervals reflect myocardial depolarization and conduction time through the atria and down the atrioventricular node (PR) and throughout the ventricle (QRS) and are weakly positively correlated ($r = 0.09$). The majority of loci that influence both PR and QRS (*SCN5A*, *SCN10A*, *TBX5* and *CAV1-2*) do so in a concordant fashion (meaning variants that prolong PR duration also prolong QRS duration). The notable exception is a region on chromosome 12, where variants in the *TBX5* locus have a concordant effect, whereas those in nearby *TBX3* have a discordant effect. By contrast, although QRS (ventricular depolarization) and QT (ventricular repolarization) are moderately positively correlated, the majority of loci (*SCN5A*, *SCN10A*, *PRKCA* and *NOS1AP*) that influence both phenotypes do so in a discordant fashion (meaning variants that prolong the QRS interval shorten the QT interval). The exception is the locus at *PLN*, where the variants have a concordant effect.

Figure 4 Expression and function of *Scn10a* in the mouse heart. (a) Neonatal ventricular myocytes from *Cntn2-eGFP* BAC transgenic mice were fluorescence-activated cell sorted and eGFP⁺ and eGFP⁻ pools were analyzed by RT-PCR. Transcripts encoding eGFP, *Cntn2* and *Scn10a* were highly enriched in the eGFP⁺ fraction. Quantitative RT-PCR demonstrated 25.7-fold enrichment of *Scn10a* $\text{Na}_v1.8$.

(b) Representative telemetric electrocardiographic recordings (lead II configuration) obtained 30 min after administration of vehicle

alone (black tracing) or the *Scn10a* $\text{Na}_v1.8$ antagonist A-803467 (green tracing). The two tracings are aligned at the onset of the QRS wave, and both PR interval and QRS interval prolongation were observed in drug-treated mice. (c) Representative intracardiac recordings showing HV intervals obtained before (Pre) and after (Post) administration of vehicle or A-803467. Significant HV prolongation was observed in drug-treated mice.



PCR (Fig. 4a), demonstrating a 25.7-fold \pm 1.1-fold (s.e.) enrichment of *Scn10a* $\text{Na}_v1.8$ in Purkinje cells compared to working ventricular myocytes ($n = 3$ for each cell type; $P = 0.002$).

Telemetric electrocardiographic recordings (lead II position) were obtained in conscious mice treated with A-803467, a potent *Scn10a* $\text{Na}_v1.8$ antagonist, which blocks $\text{Na}_v1.8$ 100 times more potently than $\text{Na}_v1.5$ with the doses used¹⁸. These studies showed a significant increase in QRS duration (11.6 ms (\pm 2.6 ms (s.e.)) to 14.5 ms (\pm 0.54 ms), $n = 7$, $P < 0.001$), whereas treatment with vehicle alone was without effect (11.4 ms (\pm 0.29 ms) to 11.9 ms (\pm 0.42 ms), $n = 7$, P value was not significant). The PR interval was also increased in drug-treated mice, from 31.4 ms (\pm 0.98 ms) to 42.5 ms (\pm 3.3 ms), $n = 7$, $P < 0.01$), whereas treatment with vehicle alone resulted in no significant change (32.6 ms (\pm 1.0 ms) to 33.4 ms (\pm 0.69 ms), $n = 7$, P value was not significant) (Fig. 4b). To further delineate the site of ventricular conduction slowing, we performed intra-cardiac recordings from mice treated with A-803467. These studies confirmed the significant increase in QRS duration (from 12.26 ms (\pm 0.62 ms) to 14.56 ms (\pm 0.58 ms), $n = 7$, $P = 0.015$), whereas treatment with vehicle alone was without significant effect (12.39 ms (\pm 0.52 ms) to 13.65 ms (\pm 0.97 ms), $n = 5$, P value was not significant). A-803467 treatment resulted in a 35.7% \pm 1.2% increase in HV interval (from 9.33 ms (\pm 0.74 ms) to 12.67 ms (\pm 1.06 ms), $P = 0.009$), whereas treatment with vehicle alone was without significant effect (10.67 ms (\pm 0.83 ms) to 11.17 ms (\pm 1.10 ms), P value was not significant) (Fig. 4c). Taken together, these data indicate that the QRS prolongation may primarily reflect conduction slowing in the specialized ventricular conduction system.

DISCUSSION

Our meta-analysis of 14 GWAS consisting of 40,407 individuals of European descent with additional genotyping in 7,170 Europeans yielded genome-wide significant associations of QRS duration with common variants in 22 loci. Variations in four of these loci (locus 1, *SCN5A-SCN10A*; locus 2, *CDKN1A*; locus 8, *TBX5*; and locus 21, *DKK1*) were previously associated with QRS duration in smaller independent studies using both candidate gene and genome-wide approaches⁷⁻⁹. The 22 loci include genes in a number of interconnected pathways, including some previously known to be involved in cardiac conduction, such as sodium channels, calcium-handling proteins and transcription factors, as well as previously unidentified processes not known to be involved in cardiac electrophysiology, such as kinase inhibitors, growth factor-related genes and others.

The electrocardiographic QRS interval reflects ventricular depolarization and conduction time. Ventricular myocyte depolarization occurs through cardiac membrane excitatory inward currents mediated by voltage-gated sodium channels¹⁹. The primary determinants of conduction velocity are the magnitude of excitatory inward

currents flowing through these sodium channels, the extent of cell-to-cell communication through gap junction–connexin coupling, and cell and tissue architecture and morphology¹⁹. Multiple pathways suggested in this study determine or modulate these key components of ventricular depolarization and conduction. Candidate genes in these pathways are briefly discussed in **Box 1**.

Our strongest association signal (locus 1) mapped in or near two voltage-gated sodium channel genes: *SCN5A* and *SCN10A*. *SCN5A* encodes the cardiac $\text{Na}_v1.5$ sodium channel and is well known for its role in cardiac conduction and other cardiovascular and electrophysiologic phenotypes^{20,21}. *SCN10A* encodes the $\text{Na}_v1.8$ sodium channel. We provide new data demonstrating that the *SCN10A* transcript and product is preferentially expressed in the mouse His-Purkinje system compared with the ventricular myocardium, and that $\text{Na}_v1.8$ channel blockers result in QRS and HV interval prolongation, indicative of a slowing of impulse propagation in the specialized ventricular conduction system and a delayed activation of the ventricular myocardium. Notably, a recent study reported shortening of the PR interval in *Scn10a* knockdown mice and concluded that $\text{Na}_v1.8$ prolongs cardiac conduction and that rs6795970, encoding the A1073V variant, is a gain-of-function allele⁸. Alternatively, the more rapid conduction they observed in the knockdown mice could reflect compensatory upregulation of TTX-sensitive currents, a phenomenon previously observed in $\text{Na}_v1.8$ -deficient DRG neurons²².

We and others demonstrated previously that, in addition to their association with QRS duration, variants in *SCN5A* and *SCN10A* are associated with atrial conduction (PR interval) and myocardial repolarization (QT interval), as well as atrial and ventricular fibrillation^{8,9,13}. These results emphasize the crucial role played by these genes in cardiac conduction and the generation of arrhythmias.

Calcium regulation is integral to impulse propagation, modulating cellular electrophysiology, including sodium channel and gap-junction function, as well as tissue architecture^{20,23,24}. Several of the loci associated with QRS duration contain genes directly related to calcium processes. As depicted in **Supplementary Figure 4** and detailed in **Box 1**, these genes encode interrelated proteins that influence Ca^{2+} signaling (*PLN* in locus 3; *PRKCA* in locus 16; and *CASQ2* in locus 18) and downstream effects (*STRN* in locus 12).

Transcription factors regulating embryonic electrophysiologic development are critical for the integrity of impulse conduction²⁵. We identified six transcription factors (*TBX3* in locus 9; *TBX5* in locus 8; *TBX20* in locus 6; *HAND1* in locus 5; *NFIA* in locus 4; and *KLF12* in locus 19) in loci associated with QRS duration. Several of these transcription factors affect cardiac morphogenesis and may influence conduction by altering cellular and tissue architecture. Notably, they may also have direct electrophysiologic consequences by modifying factors involved in impulse conduction. For example, *HAND1* and

T-box factors regulate *GJA5* (encoding connexin 40) and/or *GJA1* (encoding connexin 43), and *TBX5* binds to the *ATP2A2* (also known as *SERCA2A*) promoter²⁶.

Our study suggests a number of processes and pathways not previously known to be involved in cardiac electrophysiology, including cyclin-dependent kinase inhibitors and genes related to tumorigenesis

and cellular transformation. How these previously unidentified processes influence QRS duration remains to be defined.

In pleiotropic analyses, most variants influencing both PR and QRS interval, with the exception of *TBX3*, were concordant in effect direction, consistent with the known shared physiologic processes underlying the two traits: depolarization and conduction time in the sino-atrial node,

Box 1 Noteworthy genes within loci associated with QRS duration

Of the 22 loci identified, common variants in four loci (*SCN5A-SCN10A*, *CDKN1A*, *TBX5* and *DKK1*) were previously associated with QRS duration in genetic association studies. Mutations in two loci (*SCN5A* and *TBX5*) lead to inherited syndromes associated with conduction disease. Animal experiments show a role for several additional loci (*HAND1*, *TBX3* and *TBX5*) in cardiac ventricular conduction, as detailed below. The remainder are new QRS loci, and their role in cardiac conduction remains to be elucidated.

(1) Cardiac sodium channel genes:

- **SCN5A (locus 1):** *SCN5A* encodes the cardiac Na_v1.5 sodium channel and is well known to influence cardiac conduction, as well as other cardiovascular and electrophysiologic phenotypes^{20,21}.
- **SCN10A (locus 1):** *SCN10A* encodes the Na_v1.8 sodium channel, present in both ventricular myocardium and conduction fibers. Selective *SCN10A* blocker prolongs QRS interval.

(2) Calcium-handling proteins:

- **CASQ2 (locus 18):** *CASQ2* regulates opening of the ryanodine receptor (encoded by *RYR2*)^{28,29}. Cellular depolarization through sodium channels triggers calcium influx through L-type calcium channels, which in turn provokes *RYR2*-mediated calcium release from the sarcoplasmic reticulum. *CASQ2* mutations have been associated with catecholaminergic polymorphic ventricular tachycardia^{30,31}.
- **PLN (locus 3):** Calcium uptake into the sarcoplasmic reticulum by *SERCA2a* is regulated by *PLN* (encoding cardiac phospholamban)³². The phosphorylation state of *PLN* is dependent on signaling pathways involving phosphatases and kinases, including that encoded by *PRKCA*³². We previously demonstrated that this locus is associated with both cardiac electrical properties (QT interval duration and heart rate) and size (left ventricular end diastolic dimension) in genome-wide association analyses^{11,12,33,34}.
- **PRKCA (locus 16):** Protein kinase C alpha activity affects dephosphorylation of the sarcoplasmic reticulum Ca²⁺ ATPase-2 (*SERCA-2*) pump inhibitory protein phospholamban (*PLN*) and alters sarcoplasmic reticulum Ca²⁺ loading and the Ca²⁺ transient³⁵.
- **STRN (locus 12):** Striatin is a Ca²⁺-calmodulin binding protein that directly binds to caveolin scaffolding protein. Striatin has recently been implicated in a canine model of arrhythmogenic right ventricular cardiomyopathy^{36,37}.

(3) Transcription factors:

- **TBX3 (locus 9) and TBX5 (locus 8):** *TBX3* and *TBX5* encode transcription factors found in the cardiac conduction system. *TBX5* (activator) competes with *TBX3* (repressor) for the regulation of working myocardial genes such as *GJA1*^{38,39}. Common variations near *TBX3* and *TBX5* were associated with PR and QRS durations^{9,13}. Mutations in *TBX3* and *TBX5* have been associated with rare inherited syndromes manifested by an array of defects including ventricular structural and/or conduction defects.
- **TBX20 (locus 6):** *TBX20* demarcates the left and right ventricles⁴⁰ and mutations in *TBX20* have been implicated in multiple structural defects in mouse and human models^{41,42}.
- **HAND1 (locus 5):** *HAND1* encodes a transcription factor essential to cardiac morphogenesis⁴³, with a mutation in this gene having been identified in human hearts with septal defects⁴⁴. Overexpression of *Hand1* in the adult mouse heart leads to loss of connexin 43 (encoded by *GJA1*) expression, QRS prolongation and predisposition to ventricular arrhythmia⁴⁵.
- **NFIA (locus 4) and KLF12 (locus 19):** Little is known about the role of Nuclear Factor One (*NFIA*) and Kruppel like protein 12 (*KLF12*) in cardiac tissue development.

(4) Cyclin dependent kinase inhibitors:

- **CDKN1A (locus 2):** *CDKN1A* is a negative regulator of cell cycle entry into G2/M phase and is upregulated by *ERBB2* activation. *ERBB2*, encoding a member of the EGF-receptor family of tyrosine kinases, is essential for proper heart development, and its ligand neuregulin-1 promotes formation of the murine cardiac conduction system⁴⁶. Furthermore, *ERBB2* can modulate gap junction assembly and alter appropriate phosphorylation of connexin 43 in glial cells⁴⁷. In addition, *CDKN1A* is upregulated by *PRKCA* (locus 16)⁴⁸.
- **CDKN2C (locus 15):** A member of the family of cyclin-dependent kinase inhibitors that prevent the activation of the CDK kinases, thus functioning as a cell-growth regulator that controls cell cycle G1 progression.

(5) Other pathways:

- **CRIM1 (locus 14):** *CRIM1*, encoding a cell-surface transmembrane protein that may bind to various members of the TGF-beta superfamily of ligands, is expressed in mouse and human cardiac tissues^{49,50}. *CRIM1* interacts with bone morphogenetic proteins, which induce the expression of *CDKN1A* (p21)^{49,51}.
- **LRIG1 (locus 20):** *LRIG1* is upregulated in malignancies. It negatively regulates the proto-oncogenic, tyrosine kinase receptor family *ERBB2* (ref. 52).
- **SETBP1 (locus 11):** *SETBP1* encodes a ubiquitously expressed protein that binds to *SET* (ref. 53). The *SETBP1-SET* interaction has been hypothesized to be a component in tumor development.
- **TKT (locus 13):** Transketolase (*TKT*) is a ubiquitous enzyme used in multiple metabolic pathways, including the pentose phosphate pathway⁵⁴.
- **DKK1 (locus 21):** *DKK1*, implicated in several tumors, inhibits the Wnt signaling pathway⁵⁵. Wnt signaling is an important modulator of connexin43-dependent intercellular coupling in the heart⁵⁶. In cardiac tissue, it has an embryologic role with regard to axial development⁵⁷.
- **SIPA1L1 (locus 7):** *SIPA1L1* appears to play a role in non-canonical Wnt signaling and contributes to development⁵⁸.

